增進耐力運動表現之相關基因與蛋白質

Genes and Proteins for Enhancing Endurance Exercise Performance

10.6162/SRR.2013.125.08

曾怡鈞(Yi-Chun Tseng)；許美智(Mei-Chich Hsu)

基因促進 ； 基因禁藥 ； 基因選才 ； genetic enhancement ； gene doping ； gene selection

大專體育

125期（2013 / 06 / 01）

56 - 64

繁體中文

本文主要是探討有潛力運用於增強耐力運動表現相關的基因／蛋白質，包括紅血球生成素、血管內皮生長因子、缺氧誘導因子、血管收縮素轉換酶、過氧化小體增生活化受體γ共同活化子-1α、過氧化物酶體增殖物活化受體和磷酸烯醇式丙酮酸羧激酶之生理作用及其對耐力運動表現之影響。這些基因將可以運用於運動員的基因選才，搭配適合的營養攝取及運動訓練方式，更能將基因的優勢發揮得淋漓盡致。然而基因治療技術之進展亦可能使這些基因被用來取代傳統運動禁藥，進而發展成基因禁藥。

The purpose of this review article is to outline the effects of several functional genes/proteins including erythropoietin, vascular endothelial growth factor, hypoxia-induced factor, angiotensin-converting enzyme, peroxisome proliferator-activated receptor gamma coactivator 1-alpha, peroxisome proliferator-activated receptor delta, and phosphoenolpyruvate carboxykinase on endurance performance. These genes, if used properly, can help identify future elite athletes. However, they can also be abused as a way of gene doping.

1. 吳忠芳(2005)。耐力運動表現與血管緊縮素轉化酶。中華民國體育季刊，19(4)，10-16。
   連結：
2. 李乾瑋、許美智、蘇柏誠(2005)。運動訓練與骨骼肌微血管之再生性表現。國立體育學院論叢，16(3)，251-258。
   連結：
3. World Anti-Doping Agency. (2012). The 2013 prohibited list, Retrieved January 1, 2013, from http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/2013/WADAProhibited-List-2013-EN.pdf
4. Akhmetov, I. I.,Astranenkova, I. V.,Rogozkin, V. A.(2007).Association of PPARD gene polymorphism with human physical performance.Molecular Biology (Mosk),41(5),852-857.
5. Ameln, H.,Gustafsson, T.,Sundberg, C. J.,Okamoto, K.,Jansson, E.,Poellinger, L.(2005).Physiological activation of hypoxia inducible factor-1 in human skeletal muscle.Official Publication of the Federation of American Societies for Experimental Biology,19(8),1009-1011.
6. Arany, Z.,Foo, S. Y.,Ma, Y.,Ruas, J. L.,Bommi-Reddy, A.,Girnun, G.(2008).HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha.Nature,451(7181),1008-1012.
7. Basavarajaiah, S.,Wilson, M.,Whyte, G.,Shah, A.,McKenna, W.,Sharma, S.(2008).Prevalence of hypertrophic cardiomyopathy in highly trained athletes: Relevance to pre-participation screening.Journal of the American College of Cardiology,51(10),1003-1039.
8. Brunmair, B.,Staniek, K.,Dorig, J.,Szocs, Z.,Stadlbauer, K.,Marian, V.(2006).Activation of PPARdelta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids.Diabetologia,49(11),2713-2722.
9. Chinsomboon, J.,Ruas, J.,Gupta, R. K.,Thom, R.,Shoag, J.,Rowe, G. C.(2009).The transcriptional coactivator PGC-1alpha mediates exercise-induced angiogenesis in skeletal muscle.Proceedings of the National Academy of Sciences of the United States of America,106(50),21401-21406.
10. de la Chapelle, A.,Traskelin, A. L.,Juvonen, E.(1993).Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis.Proceedings of the National Academy of Sciences of the United States of America,90(10),4495-4499.
11. Dolgin, E.(2012).Gene therapies advance, but some see manufacturing challenges.Nature Medicine,18(12),1718-1719.
12. Folland, J.,Leach, B.,Little, T.,Hawker, K.,Myerson, S.,Montgomery, H.(2000).Angiotensinconverting enzyme genotype affects the response of human skeletal muscle to functional overload.Experimental Physiology,85(5),575-579.
13. Gao, G.,Lebherz, C.,Weiner, D. J.,Grant, R.,Calcedo, R.,McCullough, B.(2004).Erythropoietin gene therapy leads to autoimmune anemia in macaques.Blood,103(9),3300-3302.
14. Hanson, R. W.,Hakimi, P.(2008).Born to run: The story of the PEPCK-Cmus mouse.Biochimie,90(6),838-842.
15. Lin, Y. D.,Luo, C. Y.,Hu, Y. N.,Yeh, M. L.,Hsueh, Y. C.,Chang, M. Y.(2012).Instructive nanofiber scaffolds with VEGF create a microenvironment for arteriogenesis and cardiac repair.Science Translational Medicine,4(146),146ra109.
16. Lippi, G.,Guidi, G. C.(2004).Gene manipulation and improvement of athletic performances: New strategies in blood doping.British Journal of Sports Medicine,38(5),641-641.
17. Myerson, S. G.,Montgomery, H. E.,Whittingham, M.,Jubb, M.,World, M. J.,Humphries, S. E.(2001).Left ventricular hypertrophy with exercise and ACE gene insertion/deletion polymorphism: A randomized controlled trial with losartan.Circulation,103(2),226-230.
18. Narkar, V. A.,Downes, M.,Yu, R. T.,Embler, E.,Wang, Y. X.,Banayo, E.(2008).AMPK and PPARdelta agonists are exercise mimetics.Cell,134(3),405-415.
19. Neufeld, G.,Cohen, T.,Gengrinovitch, S.,Poltorak, Z.(1999).Vascular endothelial growth factor (VEGF) and its receptors.Official Publication of the Federation of American Societies for Experimental Biology,13(1),9-22.
20. O''Hagan, K. A.,Cocchiglia, S.,Zhdanov, A. V.,Tambuwala, M. M.,Cummins, E. P.,Monfared, M.(2009).PGC-1alpha is coupled to HIF-1alpha-dependent gene expression by increasing mitochondrial oxygen consumption in skeletal muscle cells.Proceedings of the National Academy of Sciences of the United States of America,106(7),2188-2193.
21. Pascual, J. A.,Belalcazar, V.,de Bolos, C.,Gutierrez, R.,Llop, E.,Segura, J.(2004).Recombinant erythropoietin and analogues: A challenge for doping control.Therapeutic Drug Monitoring,26(2),175-179.
22. Pilegaard, H.,Saltin, B.,Neufer, P. D.(2003).Exercise induces transient transcriptional activation of the PGC-1 alpha gene in human skeletal muscle.The Journal of Physiology,546(Pt 3),851-858.
23. Puigserver, P.(2005).Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha.International Journal of Obesity,29(Suppl. 1),S5-9.
24. Puthucheary, Z.,Skipworth, J. R.,Rawal, J.,Loosemore, M.,Van Someren, K.,Montgomery, H. E.(2011).The ACE gene and human performance: 12 years on.Sports Medicine,41(6),433-448.
25. Svensson, E. C.,Black, H. B.,Dugger, D. L.,Tripathy, S. K.,Goldwasser, E.,Hao, Z.(1997).Longterm erythropoietin expression in rodents and nonhuman primates following intramuscular injection of a replication-defective adenoviral vector.Human Gene Therapy,8(15),1797-1806.
26. Thompson, P. D.,Tsongalis, G. J.,Ordovas, J. M.,Seip, R. L.,Bilbie, C.,Miles, M.(2006).Angiotensin-converting enzyme genotype and adherence to aerobic exercise training.Preventive Cardiology,9(1),21-24.
27. Wang, Y. X.,Zhang, C. L.,Yu, R. T.,Cho, H. K.,Nelson, M. C.,Bayuga-Ocampo, C. R.(2004).Regulation of muscle fiber type and running endurance by PPARdelta.PLOS Biology,2(10),e294.
28. Widenfalk, J.,Lipson, A.,Jubran, M.,Hofstetter, C.,Ebendal, T.,Cao, Y.(2003).Vascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury.Neuroscience,120(4),951-960.
29. Zhang, B.,Tanaka, H.,Shono, N.,Miura, S.,Kiyonaga, A.,Shindo, M.(2003).The I allele of the angiotensin-converting enzyme gene is associated with an increased percentage of slow-twitch type I fibers in human skeletal muscle.Clinical Genetics,63(2),139-144.
30. 王杰龍、段子才(2009)。體育運動中的基因興奮劑。阜陽師範學院學報，26(2)，52-55。
31. 鍾佳蓉、張簡國平(2006)。運動禁藥─基因重組紅血球生成素。國民體育季刊，35(4)，64-67。

1. 孫佳婷(2021)。基因科技／基因禁藥研究：臺灣運動領域之認識架構。運動教練科學，61，41-51。